Tiogiva 18 microgram, inhalation powder, hard capsule

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Tiogiva is and what it is used for
2. What you need to know before you use Tiogiva
3. How to use Tiogiva
4. Possible side effects
5. How to store Tiogiva
6. Contents of the pack and other information

• if you are allergic (hypersensitive) to tiotropium or any other ingredients of this medicine (listed in section 6).
• if you are allergic (hypersensitive) to atropine or substances related to it, e.g. ipratropium or oxitropium.

Talk to your doctor or pharmacist before using Tiogiva.

• Talk to your doctor if you suffer from narrow angle glaucoma, prostate problems or have difficulty passing urine.
• If you have any kidney problems please consult your doctor.
• In case you have suffered from a myocardial infarction during the last 6 months or from any unstable or life threatening irregular heart beat or severe heart failure within the past year.
• Tiogiva is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing.
• Immediate allergic reactions such as rash, swelling, itching, wheezing or breathlessness may occur after administration of Tiogiva. If this occurs, please consult your doctor immediately.
• Inhaled medicines such as Tiogiva may cause tightness of the chest, coughing, wheezing or breathlessness immediately after inhalation. If this occurs, please consult your doctor immediately.
• Take care not to let the inhalation powder enter your eye as this may result in precipitation or worsening of narrowangle glaucoma, which is a disease of the eyes. Eye pain or discomfort, blurred vision, seeing halos around lights or coloured images in association with red eyes may be signs of an acute attack of narrow-angle glaucoma. Eye symptoms may be accompanied by headache, nausea or vomiting. You should stop using tiotropium bromide and immediately consult your doctor, preferably an eye specialist, when signs and symptoms of narrow-angle glaucoma appear.
• Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries. Therefore, please remember to pay attention to oral hygiene.
• In case you have suffered from a myocardial infarction during the last 6 months or from any unstable or life threatening irregular heart beat or severe heart failure within the past year, please inform your doctor. This is important to decide if Tiogiva is the right medicine for you to take.
• Do not use Tiogiva more frequently than once daily.

COPD

Tiogiva is not recommended for children and adolescents under 18 years.

Cystic fibrosis

The safety and efficacy of Tiogiva in children and adolescents has not been established. No data are available.

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines available without prescription.

Please tell your doctor or pharmacist if you are using/have used similar medicines for your lung disease, such as ipratropium or oxitropium.

No specific side effects have been reported when Tiogiva has been used together with other medicines used to treat COPD such as reliever inhalers, e.g. salbutamol, methylxanthines, e.g. theophylline and/or oral and inhaled steroids e.g. prednisolone.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use this medicine unless specifically recommended by your doctor.

The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.

Lactose is a source of glucose and galactose. If you have one of the rare genetic disorders galactosaemia, or glucose-galactose intolerance or congenital lactase deficiency you must talk to your doctor or pharmacist before taking this medicine.

If you inhale from more than 1 capsule of Tiogiva in a day, you should talk to your doctor immediately. You may be at a higher risk of experiencing a side effect such as dry mouth, constipation, difficulties passing urine, increased heart beat, or blurred vision.

If you forget to administer a dose, take one as soon as you remember but do not administer two doses at the same time or on the same day. Then administer your next dose as usual. Do not administer a double dose to make up for a forgotten dose.

Before you stop using Tiogiva, you should talk to your doctor or your pharmacist. If you stop using this medication the signs and symptoms of COPD may get worse.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.co.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

• The active substance is tiotropium. Each capsule contains 18 microgram tiotropium (as tiotropium bromide). During inhalation, 10 micrograms of tiotropium are delivered to the patient from each capsule from the dry powder inhaler and inhaled into the lungs.
• The other ingredients are lactose monohydrate (capsule content), hypromellose (capsule shell) and capsule printing ink (composed of shellac, black iron oxide, propylene glycol, strong ammonia solution, potassium hydroxide).

Tiogiva 18 microgram hard capsule is a colourless and transparent hard capsule, containing white powder.

This medicine is provided in blisters. The blisters are supplied in a cardboard box, depending on the pack the box will also contain a dry powder inhaler.

The dry powder inhaler has a white body with a red push button.

Package sizes:

• Cardboard box containing 30 capsules (3 blisters) with a dry powder inhaler
• Cardboard box containing 60 capsules (6 blisters) with a dry powder inhaler
• Cardboard box containing 90 capsules (9 blisters) with a dry powder inhaler
• Cardboard box containing 30 capsules (3 blisters)
• Cardboard box containing 60 capsules (6 blisters)
• Cardboard box containing 90 capsules (9 blisters)

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Manufacturer

If this is your first time using an inhaler of any kind, make sure you have had sufficient training from your healthcare professional before you use the dry powder inhaler.

Your dry powder inhaler comes with capsules in blister packaging. Use, where applicable, the new dry powder inhaler provided with your medicine. Each dry powder inhaler should be replaced after a maximum of 180 days.

The parts of your dry powder inhaler include: (see Figure A)

1. Dust cap (lid)
2. Mouthpiece
3. Mouthpiece ridge
4. Base
5. Centre chamber
6. Piercing Button
7. Air intake vents

Step 1: Opening your dry powder inhaler

After removing your dry powder inhaler from the pouch:

• Open the dust cap (lid) by lifting the dust cap (lid). (see Figure B)

• Pull the dust cap (lid) upwards away from the base to expose the mouthpiece. (see Figure C)

• Open the mouthpiece by pulling the mouthpiece ridge up and away from the base so the centre chamber is showing. (see Figure D)

Step 2: Inserting the capsule into your dry powder inhaler

Remove a capsule from the blister (only immediately before use (see Blister Handling) and place the capsule in the centre chamber of your dry powder inhaler.

It does not matter which side of the capsule is up or down (See Figure E)

Close the mouthpiece firmly against the grey base until you hear a click. (see Figure F)

Leave the dust cap (lid) open.

Step 3: Piercing the capsule:

• Hold your dry powder inhaler with the mouthpiece pointed up. (see Figure G)
• Press the piercing button once fully in until it stops, then release. This is how you make holes in the capsule so that you get your medicine when you breathe in.
• Do not press the piercing button more than one time.
• Do not push upward on the base while pressing the piercing button. This may cause the device to open, such as for cleaning (see Caring for and Storing Your Dry Powder Inhaler).
• Keep your inhaler in an upright position.
• Do not shake your dry powder inhaler.
• The piercing of the capsule may produce small capsule pieces. Some of these small pieces may pass through the screen of your MRX003-R into your mouth or throat when you breathe in your medicine. It is not harmful if these pieces are swallowed or inhaled.

Step 4: Taking your full daily dose (2 inhalations from the same capsule)

Breathe out completely in 1 breath, emptying your lungs of any air. (see Figure H)

Important: Do not breathe into your dry powder inhaler.

With your next breath, take your medicine:

• Hold your head in an upright position while you are looking straight ahead. (see Figure I)
• Raise your dry powder inhaler to your mouth in a horizontal position. Do not block the air intake vents.
• Close your lips tightly around the mouthpiece.
• Breathe in slowly and deeply until your lungs are full. You should hear and/or feel the capsule vibrate (rattle).
• Hold your breath for a few seconds and, at the same time, take your dry powder inhaler out of your mouth.
• Breath normally again. Resume normal breathing. Repeat step 4 once more, in order to empty the capsule completely.

Important: Do not press the piercing button again. Remember: To get your full medicine dose each day, you must breathe in 2 times from the same capsule. Make sure you breathe out completely each time before you breathe in from your dry powder inhaler.

After taking your daily dose, open the mouthpiece and tip out the used capsule without touching it, into your rubbish bin.

• Remove any capsule pieces or powder build up, without touching it, by turning your dry powder inhaler upside-down and gently, but firmly, tapping it. (see Figure J)
• Close the mouthpiece and dust cap for storage.

Store the dry powder inhaler at ambient temperature (not more than 30°C).

Do not store your dry powder inhaler and tiotropium capsules (blisters) in a damp moist place. Always store tiotropium capsules in the sealed blisters.

Clean the dry powder inhaler monthly. (see Figure K).

• Do not use cleaning agents or detergents.
• Do not place your dry powder inhaler in the dishwasher for cleaning.

It takes 24 hours to air-dry your dry powder inhaler after you clean it:

• Do not use a hair dryer to dry your dry powder inhaler
• Do not use your dry powder inhaler when it is wet. If needed, you may clean the outside of the mouthpiece with a clean damp cloth.

Cleaning Steps:

• Open the dust cap and mouthpiece.
• Open the base by pushing the piercing button upwards.
• Look in the centre chamber for capsule pieces or powder build-up. If seen, tap out.
• Rinse your dry powder inhaler with warm water, pressing the button a few times so that the centre chamber and the piercing needle is under the running water. Check that any powder build-up or capsule pieces are removed.
• Dry your dry powder inhaler well by tipping the excess water out on a paper towel. Air-dry afterwards, leaving the dust cap, mouthpiece, and base open by fully spreading it out so that it dries completely. All parts of the dry powder inhaler should be completely dry prior to use.

Each day, separate only 1 of the blisters from the blister card by tearing along the perforated line. (see Figure L)

Remove the tiotropium capsule from the blister (see Figure M):

• Do not cut the foil or use sharp instruments to take out the capsule from the blister.
• Bend 1 of the blister corners with an arrow and separate the aluminium foil layers.
• Peel back the printed foil until you see the whole capsule. Do this only immediately before use.
• If you have opened more than 1 blister to the air, the extra capsule should not be used and should be thrown away.

Each tiotropium capsule contains only a small amount of powder. (see Figure N) This is 1 full dose taken with two successive breaths.

Do not open the tiotropium capsule or it may not work.

• The dry powder inhaler is intended to be used by adults (minimum 18 years of age) who require pulmonary administration of a medicinal substance.
• There are no known contraindications for the dry powder inhaler
• There are no special precautions for dry powder inhaler disposal
• Do not use the device if it is visibly damaged or if an old capsule remains in the device
• Consult a healthcare professional in case of any abnormal reactions to the dry powder inhaler use.

Legal Manufacturer of the dry powder inhaler MRX003-R